PTAB Upholds Patent Claims on Methods of Using Ravicti®, PTAB Litigation Blog
Visit the Jones Day PTAB Litigation Blog.
On November 3, 2016, the PTAB issued a Final Written Decision upholding a Horizon Therapeutics LLC (“Horizon”) patent, U.S. 8,642,012 (the ’012 patent), relating to use of Ravicti® (glycerol phenylbutyrate) for treating inborn urea cycle disorders (UCDs). The ’012 patent was challenged by generic-drug maker Par Pharmaceutical Inc. (“Par”) after Par was sued in ANDA litigation. Par’s IPR petition was joined with Lupin’s later-filed petition that raised substantially similar grounds. (See cases IPR2015-01117 and IPR2016-00283, joined.)
Read the full article at ptablitigationblog.com.
Insights by Jones Day should not be construed as legal advice on any specific facts or circumstances. The contents are intended for general information purposes only and may not be quoted or referred to in any other publication or proceeding without the prior written consent of the Firm, to be given or withheld at our discretion. To request permission to reprint or reuse any of our Insights, please use our “Contact Us” form, which can be found on our website at www.jonesday.com. This Insight is not intended to create, and neither publication nor receipt of it constitutes, an attorney-client relationship. The views set forth herein are the personal views of the authors and do not necessarily reflect those of the Firm.
